Hematology
News
COVID-19–associated coagulopathy
Early recognition and anticoagulation is imperative to improve clinical outcomes in COVID-19–associated coagulopathies.
From the Journals
COVID-19 pulmonary severity ascribed to coagulation differences
Feature
EHA and TIF explore how COVID-19 is affecting thalassemia and SCD patients
Feature
Can convalescent plasma treat COVID-19 patients?
How COVID-19 patients can receive convalescent plasma, who is eligible to donate, and early results of treatment.
News from the FDA/CDC
FDA okays emergency use of convalescent plasma for seriously ill COVID-19 patients
“It’s crucial that data be captured for every patient so that we really understand what safety and effectiveness looks like on as close to a real-...
From the Journals
Sickle cell patients with vitamin D deficiency prone to more ED visits, longer stays
Screening for vitamin D deficiency may show benefits, authors suggest.
Conference Coverage
After PCI, stopping antiplatelet therapy for surgery appears safe
NATIONAL HARBOR, MD. –
Conference Coverage
Fear drives activity changes in hemophilia patients
Conference Coverage
BCL11A-directed gene therapy advances in sickle cell disease
ORLANDO – A phase 2/3 study is planned to assess the gene therapy in a larger group of patients with sickle cell disease.
Conference Coverage
Aspirin plus a DOAC may do more harm than good in some
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication...
News from the FDA/CDC
FDA approves treatment for sickle cell pain crises
Crizanlizumab-tmca (Adakveo) is approved for patients with sickle cell disease who are aged 16 years and older.